EyeSense Attracts Lee’s Pharmaceutical Holdings as Strategic Investor
Strategic partnership to develop and commercialize a novel continuous blood glucose monitoring system for diabetes patients.
Basel, Switzerland/Hong Kong, 27th November 2014 — EyeSense AG (“EyeSense”), a leading developer of novel continuous blood glucose monitoring systems for diabetes patients, today announced that it has entered into a strategic partnership with Lee’s Pharmaceutical Holdings Limited (“Lee’s PHARM” – Hong Kong Stock Exchange; Stock Code 950). By combining Lee’s PHARM’s strong presence in the dynamically growing Chinese and South Asian markets and EyeSense’s unique glucose sensing technology, the partners agreed to develop and commercialize a new continuous blood glucose monitoring system for diabetes patients. Lee’s PHARM acquired a minority equity stake in EyeSense and Powder Pharmaceuticals Inc., (“Powder”), an associated company of Lee’s PHARM, attained rights for the development and future commercialization of the device in China and other South Asian countries, except for Japan. The partnership and investment will allow an expansion of the availability of innovative continuous blood glucose monitoring systems to further improve and individualize the treatment of the steadily growing number of diabetes patients. The financing was led by Rosetta Capital and supported by existing EyeSense investors LSP and BioMedInvest – to the entire press release.